
|Videos|April 12, 2017
Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer
Author(s)Hope S. Rugo, MD
Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5
































